Business
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
New Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a
About this update from Genedx Holdings Corp.
[{"type":"text","content":"\nNew Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients\n\n\n STAMFORD, Conn.--(BUSINESS WIRE)--\nGeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data - powered by GeneDx’s robust database - to improve all stages of drug development. The new offering is part of GeneDx’s ongoing investment to deliver personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery.\n\n\nToday’s drug discovery and development process is not scalable to meet society’s growing needs. On average, developing a new therapy costs $2.6B, takes 12 years, and fails 90% of the time. This data represents today's long and expensive clinical development cycles that too often fail due to safety and/or efficacy issues.1,2 These high costs, lengthy development periods, and overwhelming failure rates are unsustainable, especially as science and technology advance to address critical therapy gaps both in the U.S. and globally.\n\n\nGenetic data is a powerful tool that can significantly enhance the therapeutic development process, including reducing costs, accelerating timelines, and increasing success rates1. With access to genetic diagnoses continuing to expand, the impact of genetics on therapeutic development is growing. With more than 700,000 clinical exomes and genomes, GeneDx’s industry leading dataset is one of the most sophisticated in the industry and can now be leveraged as a solution for biopharmaceutical companies to drive evidence-based decision making and accelerate the development of new treatments.\n\n\n\"With nearly 25 years of expertise in clinical genetic data, GeneDx holds a wealth of genetic evidence that plays a critical role in transforming patient care and unlocking new drug development opportunities,\" said Melanie Duquette, Chief Growth Officer at GeneDx. \"GeneDx Discover is a data-driven solution that empowers our biopharma partners to better understand the genetic underpinnings of diseases, their prevalence in diverse patient populations and accelerate the development of targeted therapies—helping bring effective treatments to more patients, ...